Abstract:The therapeutic value of vascular targeted photodynamic therapy (VTP) for cancer has already been recognized in the clinic: TOOKAD ® has been clinically approved in Europe and Israel for treatment of men with low-risk prostate cancer. When light is applied shortly after intravenous administration of the photosensitizer, the damage is primarily done to the vasculature. This results in vessel constriction, blood flow stasis, and thrombus formation. Subsequently, the tumor is killed due to oxygen and nutrient deprivation. To further increase treatment specificity and to reduce undesired side effects such as damaging to the surrounding healthy tissues, efforts have been made to selectively target the PS to the tumor vasculature, an approach named molecular targeted VTP (molVTP). Several receptors have already been explored for this approach, namely CD13, CD276, Extra domains of fibronectin (A, B), Integrin [Formula: see text]v[Formula: see text]3, Neuropilin-1, Nucleolin, PDGFR[Formula: see text], tissue factor, and VEGFR-2, which are overexpressed on tumor vasculature. Preclinical studies have shown promising results, further encouraging the investigation and future application of molVTP, to improve selectivity and efficacy of cancer treatment. This strategy will hopefully lead to even more selective treatments for many cancer patients.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: How to specifically target tumor blood vessels through molecular - targeted photodynamic therapy (molVTP) in order to improve the selectivity and efficacy of cancer treatment and reduce the adverse effects on surrounding healthy tissues. Specifically, the authors explored a variety of receptors and molecular targets (such as CD13, CD276, extra - domains A and B of fibronectin, integrin αvβ3, neural cell adhesion molecule - 1, nucleolin, PDGFRβ, tissue factor and VEGFR - 2). These targets are over - expressed in tumor blood vessels and can thus be used as targeted delivery carriers for photosensitizers (PS).
### Background of Photodynamic Therapy (PDT)
Photodynamic Therapy (PDT) is a treatment method that utilizes the synergistic effect of photosensitizers (PS), light of a specific wavelength, and oxygen to produce cytotoxicity. Using these three components alone is harmless, but when they act together, the activated photosensitizer transfers energy to oxygen to form cytotoxic reactive oxygen species (ROS). ROS can damage biomolecules (such as lipids, proteins, and nucleic acids), thereby killing cancer cells, destroying tumor blood vessels, and inducing inflammation and immune responses.
### Vascular - Targeted Photodynamic Therapy (VTP)
Vascular - Targeted Photodynamic Therapy (VTP) applies light shortly after intravenous injection of photosensitizers, mainly damaging tumor blood vessels. This will lead to vasoconstriction, blood flow stasis and thrombosis, and finally tumor necrosis due to hypoxia and lack of nutrients. VTP has the following advantages over traditional PDT:
1. **Reduce the photosensitive period**: The photosensitizers used in traditional PDT are usually very hydrophobic and stay in the body for a long time, and patients may experience a long - term photosensitivity.
2. **Reduce damage to surrounding healthy tissues**: In traditional PDT, although the light is applied locally, due to the poor selectivity of photosensitizers for tumors, the surrounding healthy tissues may also be damaged.
3. **Overcome the problem of acute hypoxia**: There may be acute hypoxia in some areas inside the tumor, which affects the generation of ROS, while the oxygen supply in tumor blood vessels is relatively sufficient, and the blood vessels can directly contact the photosensitizers.
### Molecular - Targeted VTP (molVTP)
In order to further improve the selectivity and efficacy of VTP, researchers have developed Molecular - Targeted VTP (molVTP). This method specifically delivers photosensitizers to specific receptors in tumor blood vessels by binding them with specific targeting molecules (such as peptides, antibodies or nanocarriers). Several targeting molecules mentioned in the article include:
- **CD13/aminopeptidase N**: Over - expressed in tumor blood vessels and can be targeted with NGR peptides.
- **CD276**: An immunomodulatory molecule over - expressed in tumor blood vessels and various tumors.
- **Extra - domains A and B of fibronectin (ED - A and ED - B)**: Barely expressed in normal adult tissues but highly expressed in tumor - derived neovasculature.
- **Integrin αvβ3**: Widely present in tumor - derived neovasculature and can be targeted with RGD peptides.
- **Neural cell adhesion molecule - 1 (Neuropilin - 1)**: Participates in tumor vascularization and progression and can be over - expressed in some tumor cells.
These targeting strategies aim to increase the accumulation of photosensitizers in tumor blood vessels, enhance the treatment effect, and reduce side effects.